Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Sagara Y, et al. Among authors: sato n. Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3. Breast Cancer Res Treat. 2018. PMID: 29971625 Clinical Trial.
[Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial].
Sano M, Tabei T, Suemasu K, Yanagita Y, Yamamoto N, Asaga T, Ando J, Fujii H, Inoue K, Sato N, Takei H, Kurosumi M, Honma K, Kimura M. Sano M, et al. Among authors: sato n. Gan To Kagaku Ryoho. 2006 Oct;33(10):1411-5. Gan To Kagaku Ryoho. 2006. PMID: 17033229 Clinical Trial. Japanese.
No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan.
Saeki T, Sano M, Komoike Y, Sonoo H, Honjyo H, Ochiai K, Kobayashi T, Aogi K, Sato N, Sawai S, Miyoshi Y, Takeuchi M, Takashima S. Saeki T, et al. Among authors: sato n. Int J Clin Oncol. 2008 Feb;13(1):8-11. doi: 10.1007/s10147-007-0728-0. Epub 2008 Feb 29. Int J Clin Oncol. 2008. PMID: 18307013
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H. Toi M, et al. Among authors: sato n. Cancer Sci. 2011 Apr;102(4):858-65. doi: 10.1111/j.1349-7006.2011.01867.x. Epub 2011 Feb 10. Cancer Sci. 2011. PMID: 21231986 Free article.
5,449 results